Recent clinical trials regarding the intravitreal injection of antivascular endothelial growth factor (VEGF) agents (ranibizumab, bevacizumab, pegaptanib, and aflibercept) have shown excellent results in the treatment of angiogenic pathologies including choroidal neovascularization, macular edema, proliferative diabetic retinopathy, and neovascular glaucoma. The gene discussed is VEGFA; the disease is macular retinal edema.